82 FR 11235 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 33 (February 21, 2017)

Page Range		11235-11235
FR Document		2017-03306

The inventions listed below are owned by an agency of the U.S. Government.

Federal Register, Volume 82 Issue 33 (Tuesday, February 21, 2017)

[Federal Register Volume 82, Number 33 (Tuesday, February 21, 2017)]
[Notices]
[Page 11235]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-03306]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by emailing the indicated licensing contact at the National Heart, 
Lung, and Blood, Office of Technology Transfer and Development Office 
of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, 
MD 20892-2479; telephone: 301-402-5579. A signed Confidential 
Disclosure Agreement may be required to receive any unpublished 
information.

SUPPLEMENTARY INFORMATION: The following inventions are available for 
licensing in accordance with 35 U.S.C. 209 and 37 CFR part 404 to 
achieve expeditious commercialization of results of federally-funded 
research and development. Technology description follows.

Methods for Improving Drug Delivery to the Central Nervous System

    The invention relates to the uses of the tricyclic antidepressant 
amitriptyline, its bioactive metabolites, and other LPA1R activators to 
improve the bioavailability and delivery of therapeutics to the central 
nervous system. This invention demonstrates that amitriptyline and 
other agents selectively decrease P-glycoprotein (P-gp) transport 
activity by ligand activation of lysophosphatidic acid 1 receptor 
(LPA1R) at the blood-brain barrier. P-gp is an effective target for 
increasing drug delivery to the brain (CNS) for two major reasons: (1) 
Its substrates include a large portion of on-the-market drugs, 
including chemotherapeutics, and (2) its directionality results in a 
net efflux of drugs from the brain. Additionally, specifically 
targeting P-gp through LPA1R activation bypasses the clinical 
challenges resulting from the toxicity of substrate inhibitors of P-gp. 
This invention describes the inhibition of drug efflux by P-gp 
transport; thus, co-administration of therapeutics with amitriptyline 
and other LPA1R activators provides a method for increasing drug 
delivery to the CNS, and improving overall drug efficacy. Moreover, 
drug delivery to other barrier tissues will also be enhanced where a 
similar LPA1R-P-gp activity relationship exists.
    Potential Commercial Applications:
     Drug Delivery to the CNS.
     Co-administration of therapeutics.
     Blood-brain-barrier permeability.
    Development Stage:
     Early stage.
    Inventors: Ronald Cannon and David Banks (NIEHS).
    Publications:
     Cannon et al., Neurosci Lett. 2017 Feb 3;639:103-113 doi: 
10.1016/j.neulet.2016.12.049.
     Mesev, et al., Mol Pharmacol. 2017 Jan 24. pii: 
mol.116.107169. doi: 10.1124/mol.116.107169.
     More, et al., J Cereb Blood Flow Metab. 2016 May 18. pii: 
0271678X16650216.
     Miller, et. al, Curr Pharm Des. 2014;20(10):1463-71. 
Review.
     Cartwright, et al., J Cereb Blood Flow Metab. 2013 
Mar;33(3):381-8. doi: 10.1038/jcbfm.2012.174.
    Intellectual Property: HHS Reference No. E-179-2065/0 and/1; U.S. 
Provisional Patent Applications 62/332,888 filed May 6, 2016, and 62/
453,718 filed February 2, 2017, respectively.
    Licensing Contact: Michael Shmilovich, Esq., CLP; 301-435-5019; 
[email protected].

    Dated: February 10, 2017.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2017-03306 Filed 2-17-17; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 82, No. 33 / Tuesday, February 21, 2017 / Notices 11235

Contact Person: Reigh-Yi Lin, Ph.D., 93.846–93.878, 93.892, 93.893, National LPA1R activation bypasses the clinical
Scientific Review Officer, Center for Institutes of Health, HHS) challenges resulting from the toxicity of
Scientific Review, 6701 Rockledge Drive, Dated: February 14, 2017. substrate inhibitors of P-gp. This
Bethesda, MD 20892, 301–827–6009,
Natasha M. Copeland, invention describes the inhibition of
lin.reigh-yi@nih.gov.
Program Analyst, Office of Federal Advisory drug efflux by P-gp transport; thus, co-
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR 16– Committee Policy. administration of therapeutics with
366—Dual Purpose with Dual Benefit: [FR Doc. 2017–03281 Filed 2–17–17; 8:45 am] amitriptyline and other LPA1R
Research in Biomedicine and Agriculture. BILLING CODE 4140–01–P
activators provides a method for
Date: March 21, 2017. increasing drug delivery to the CNS, and
Time: 8:00 a.m. to 6:00 p.m. improving overall drug efficacy.
Agenda: To review and evaluate grant DEPARTMENT OF HEALTH AND Moreover, drug delivery to other barrier
applications. HUMAN SERVICES tissues will also be enhanced where a
Place: Hyatt Regency Bethesda, One similar LPA1R–P-gp activity
Bethesda Metro Center, 7400 Wisconsin National Institutes of Health
Avenue, Bethesda, MD 20814.
relationship exists.
Contact Person: Tera Bounds, DVM, Ph.D.,
Potential Commercial Applications:
Scientific Review Officer, Center for
Government-Owned Inventions; • Drug Delivery to the CNS.
Scientific Review, National Institutes of
Availability for Licensing • Co-administration of therapeutics.
Health, 6701 Rockledge Drive, Room 3214, • Blood-brain-barrier permeability.
AGENCY: National Institutes of Health, Development Stage:
MSC 7808, Bethesda, MD 20892, 301–435– HHS.
2306, boundst@csr.nih.gov. • Early stage.
ACTION: Notice. Inventors: Ronald Cannon and David
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Banks (NIEHS).
SUMMARY: The inventions listed below Publications:
Fellowships: Risk, Prevention and Health are owned by an agency of the U.S.
Behavior Overflow. • Cannon et al., Neurosci Lett. 2017
Government. Feb 3;639:103–113 doi: 10.1016/
Date: March 21, 2017.
Time: 9:00 a.m. to 1:00 p.m. FOR FURTHER INFORMATION CONTACT: j.neulet.2016.12.049.
Agenda: To review and evaluate grant Licensing information may be obtained • Mesev, et al., Mol Pharmacol. 2017
applications. by emailing the indicated licensing Jan 24. pii: mol.116.107169. doi:
Place: National Institutes of Health, 6701 contact at the National Heart, Lung, and 10.1124/mol.116.107169.
Rockledge Drive, Bethesda, MD 20892 Blood, Office of Technology Transfer • More, et al., J Cereb Blood Flow
(Telephone Conference Call). Metab. 2016 May 18. pii:
Contact Person: Stacey C. FitzSimmons,
and Development Office of Technology
Transfer, 31 Center Drive, Room 4A29, 0271678X16650216.
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of MSC2479, Bethesda, MD 20892–2479; • Miller, et. al, Curr Pharm Des.
Health, 6701 Rockledge Drive, Room 3114, telephone: 301–402–5579. A signed 2014;20(10):1463–71. Review.
MSC 7808, Bethesda, MD 20892, (301) 451– Confidential Disclosure Agreement may • Cartwright, et al., J Cereb Blood
9956, fitzsimmonss@csr.nih.gov. be required to receive any unpublished Flow Metab. 2013 Mar;33(3):381–8. doi:
Name of Committee: Center for Scientific information. 10.1038/jcbfm.2012.174.
Review Special Emphasis Panel; Urology and Intellectual Property: HHS Reference
SUPPLEMENTARY INFORMATION: The
Urogynecology Small Business Applications. No. E–179–2065/0 and/1; U.S.
following inventions are available for
Date: March 21, 2017. Provisional Patent Applications 62/
licensing in accordance with 35 U.S.C.
Time: 9:00 a.m. to 12:00 p.m. 332,888 filed May 6, 2016, and 62/
Agenda: To review and evaluate grant 209 and 37 CFR part 404 to achieve
453,718 filed February 2, 2017,
applications. expeditious commercialization of
respectively.
Place: National Institutes of Health, 6701 results of federally-funded research and Licensing Contact: Michael
Rockledge Drive, Bethesda, MD 20892 development. Technology description Shmilovich, Esq., CLP; 301–435–5019;
(Telephone Conference Call). follows. shmilovm@mail.nih.gov.
Contact Person: Ganesan Ramesh, Ph.D.,
Center for Scientific Review, National Methods for Improving Drug Delivery Dated: February 10, 2017.
Institutes of Health, 6701 Rockledge Dr., to the Central Nervous System Michael Shmilovich,
Room 2182, MSC 7818, Bethesda, MD 20892, The invention relates to the uses of Senior Licensing and Patenting Manager,
ganesan.ramesh@nih.gov. the tricyclic antidepressant National Heart, Lung, and Blood Institute,
Name of Committee: Center for Scientific amitriptyline, its bioactive metabolites, Office of Technology Transfer and
Review Special Emphasis Panel; Member and other LPA1R activators to improve Development.
Conflict: Topics in drug discovery and
the bioavailability and delivery of [FR Doc. 2017–03306 Filed 2–17–17; 8:45 am]
clinical field studies.
Date: March 21, 2017. therapeutics to the central nervous BILLING CODE 4140–01–P

Time: 10:00 a.m. to 5:00 p.m. system. This invention demonstrates
Agenda: To review and evaluate grant that amitriptyline and other agents
applications. selectively decrease P-glycoprotein (P- DEPARTMENT OF HEALTH AND
Place: National Institutes of Health, 6701 gp) transport activity by ligand HUMAN SERVICES
Rockledge Drive, Bethesda, MD 20892 activation of lysophosphatidic acid 1
(Virtual Meeting). receptor (LPA1R) at the blood-brain National Institutes of Health
Contact Person: Liangbiao Zheng, Ph.D., barrier. P-gp is an effective target for
Scientific Review Officer, Center for Eunice Kennedy Shriver National
increasing drug delivery to the brain
sradovich on DSK3GMQ082PROD with NOTICES

Scientific Review, National Institutes of Institute of Child Health & Human
Health, 6701 Rockledge Drive, Room 3202, (CNS) for two major reasons: (1) Its
Development; Notice of Closed
MSC 7808, Bethesda, MD 20892, 301–996– substrates include a large portion of on-
Meetings
5819, zhengli@csr.nih.gov. the-market drugs, including
(Catalogue of Federal Domestic Assistance chemotherapeutics, and (2) its Pursuant to section 10(d) of the
Program Nos. 93.306, Comparative Medicine; directionality results in a net efflux of Federal Advisory Committee Act, as
93.333, Clinical Research, 93.306, 93.333, drugs from the brain. Additionally, amended (5 U.S.C. App.), notice is
93.337, 93.393–93.396, 93.837–93.844, specifically targeting P-gp through hereby given of the following meetings.

VerDate Sep<11>2014 17:15 Feb 17, 2017 Jkt 241001 PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 E:\FR\FM\21FEN1.SGM 21FEN1

Document Created: 2018-02-01 15:04:29
Document Modified: 2018-02-01 15:04:29

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice.
Contact		Licensing information may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure Agreement may be required to receive any unpublished information.
FR Citation		82 FR 11235

82 FR 11235 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 82, Issue 33 (February 21, 2017)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health